Member Info for Mittenator

It’s been trading a week, ffs!
Serious investors will wait weeks/months for the stock to settle in and aren’t interested in quick wins but long term growth and ROI. They’re waiting for the short term players to move on.

This RNS was planned way before listing IMO. I expect they’ll have numerous RNS updates/contracts in place ready and waiting with pre-determined dates of delivery to the market. All in the pre-listing preparation.

A good RNS but not GREAT.

Prefer a steady riser tbh, without the hit and runs

Sell on good newsers. Get rid of them 1st.

For the De-rampers,

Please chat amongst yourselves here.

Thanks.

Dear EliteTrader,

“Great oaks from little acorns grow”

Kind regards,

Mittenator

Some large trades which are multiples of the Average Daily Turnover are published up to three days after execution, which can distort the numbers. See LSE recent trades.

Kettle: KNB are probably a long way down that road already. They were planning on listing late 2019 but didn’t until we left the EU single market and customs Union on 31 Dec 2020 . Read between the lines.

Kettle: I would argue that a treatment course of medicinal cannabinoids is significantly cheaper for the NHS to prescribe than conventional drugs. Take a look at the conditions that cannabinoids can help with (evidence-based research) and look at the current cost price to NHS of associated drug/cost per treatment course. DYOR

Be encouraging if can end the week at 34 and week after 40p....

Looks like MM’s need stock so upping the Bid price higher than the SP!

KNB, having focused on banks and meeting institutions pre-listing and seeing a UK cannabis perception change, it’s only a matter of time before II’s start building their positions. That’s when the excitement starts!

Untapped European Market

Pre-Commercialisation SP - stabilising circa 25p
Post-Commercialisation SP (1st RNS) -

Should everyone de-ramp so you can buy back in sub 15 then? Haha

No one is going to argue that this is currently a speculative buy. Sentiment is subjective so without objective RNS updates, pump and dump will likely continue. The timing of the listing should not be underestimated. These are smart cookies at KNB. Operation Scale-Up is well underway and I’m sure they already have a timeline for future updates/revenue projections over next 12 months at least.

...

Patient access to products within months!

...

DYOR

Numerous patents pending which is extremely encouraging. Can’t see any bad news on the horizon, only good. Volatility unsurprising - just normal cycle of events following IPO. Patience is key. They’re not ‘just another cannabis stock’, they have a number of USP’s and could licence out their IP’s generating significant revenue.

My previous trades via HL haven’t shown